Literature DB >> 34271311

How we treat primary central nervous system lymphoma.

T Calimeri1, S Steffanoni1, F Gagliardi2, A Chiara3, A J M Ferreri4.   

Abstract

Entities:  

Year:  2021        PMID： 34271311     DOI： 10.1016/j.esmoop.2021.100213

Source DB:  PubMed          Journal:  ESMO Open        ISSN： 2059-7029


× No keyword cloud information.
  3 in total

1.  Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.

Authors:  Tadashi Okamura; Hiroki Hosoi; Takeshi Matsufusa; Yuina Akagi; Ryuta Iwamoto; Hideki Kosako; Shogo Murata; Toshiki Mushino; Shin-Ichi Murata; Takashi Sonoki
Journal:  Ann Hematol       Date:  2022-01-27       Impact factor: 3.673

2.  The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?

Authors:  Luís Alberto de Pádua Covas Lage; Vinícius Araújo Soares; Thales Dalessandro Meneguin; Hebert Fabrício Culler; Cadiele Oliana Reichert; Mayara D'Auria Jacomassi; Diego Gomes Cândido Reis; Maria Cláudia Nogueira Zerbini; Renata de Oliveira Costa; Vanderson Rocha; Juliana Pereira
Journal:  Radiat Oncol       Date:  2022-10-22       Impact factor: 4.309

3.  Intraparenchymal Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Report.

Authors:  Pedram Laghaei Farimani; Vishwathsen Karthikeyan; Mostafa Fatehi; Adrian Levine; Graham W Slack; Ian R Mackenzie; Charles Haw
Journal:  Cureus       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.